DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong ...

The stock's fall snapped a two-day winning streak.

Key Insights DexCom's estimated fair value is US$116 based on 2 Stage Free Cash Flow to Equity DexCom is estimated ...

DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was ...

Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was partly thanks to its solid quarterly results ...

In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.

DexCom Inc. closed 34.58% short of its 52-week high of $132.26, which the company reached on May 17th.

Dexcom Inc. defeated investor allegations the glucose monitor maker exaggerated its ability to tap into the market of ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of ...

The S&P 500 jumped 1.5% on Friday, May 2, 2025, as the latest jobs report revealed a strong pace of hiring in April despite ...

Glucose tracking is a natural part of Oura’s $75 million investment from Dexcom.

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong first-quarter 2025 performance and a series of favorable coverage decisions are ...